Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC). This is an ASCO Meeting Abstract from ...
Tilman Todenhöfer; Stefan Wirths; Claus Hann von Weyhern; Stefan Heckl; Marius Horger; Joerg Hennenlotter; Arnulf Stenzl; Lothar Kanz; Christian Schwentner In the present case, a combination of drugs ...
The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
Q: What are the pain referral patterns in patients with renal cell carcinoma? —Carlton J. Lewis, DO, Lufkin, Tex. A: Patients with renal cell carcinoma are generally asymptomatic until their tumors ...
Adjuvant pembrolizumab therapy after surgery for renal-cell carcinoma was approved on the basis of a significant improvement in disease-free survival in the KEYNOTE-564 trial. Whether the results ...
Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled trial, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback